D. E. Shaw & Co., Inc. Cyteir Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.62 - $4.4 $21,594 - $58,652	-13,330 Reduced 18.55%	58,529 $175,000
Q1 2022 May 16, 2022	BUY	$3.39 - $10.51 $163,214 - $506,014	48,146 Added 203.04%	71,859 $271,000
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $233,098 - $455,526	23,713 New	23,713 $270,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.